Skip to main content
Addgene

CIP2Aprom865bp-pGL4.10Luc
(Plasmid #60869)

Print

Full plasmid sequence is not available for this item.

Ordering

This material is available to academics and nonprofits only.
Item Catalog # Description Quantity Price (USD)
Plasmid 60869 Standard format: Plasmid sent in bacteria as agar stab 1 $85
Add to Cart

Backbone

  • Vector backbone
    pGL4.10(luc2)
  • Backbone manufacturer
    Promega
  • Backbone size w/o insert (bp) 4242
  • Vector type
    Luciferase ; Promoterless

Growth in Bacteria

  • Bacterial Resistance(s)
    Ampicillin, 100 μg/mL
  • Growth Temperature
    37°C
  • Growth Strain(s)
    DH5alpha
  • Copy number
    High Copy

Gene/Insert

  • Gene/Insert name
    865 bp promoter fragment of Cancerous Inhibitor of PP2A
  • Alt name
    865 bp CIP2A promoter
  • Species
    H. sapiens (human)
  • Insert Size (bp)
    865
  • Entrez Gene
    CIP2A (a.k.a. KIAA1524, NOCIVA, p90)

Terms and Licenses

Trademarks:
  • Zeocin® is an InvivoGen trademark.

Depositor Comments

Then various length luciferase promoter constructs were created using the Deletion Kit for Kilo-Sequencing (Takara Bio Inc., Japan) as per the manufacturer’s instructions. Please note that there are some discrepancies between Addgene's quality control sequences and the depositor's sequence. The depositor noted that these discrepancies do NOT affect plasmid function.

How to cite this plasmid ( Back to top)

These plasmids were created by your colleagues. Please acknowledge the Principal Investigator, cite the article in which the plasmids were described, and include Addgene in the Materials and Methods of your future publications.

  • For your Materials & Methods section:

    CIP2Aprom865bp-pGL4.10Luc was a gift from Jukka Westermarck (Addgene plasmid # 60869 ; http://n2t.net/addgene:60869 ; RRID:Addgene_60869)

  • For your References section:

    ETS1 mediates MEK1/2-dependent overexpression of cancerous inhibitor of protein phosphatase 2A (CIP2A) in human cancer cells. Khanna A, Okkeri J, Bilgen T, Tiirikka T, Vihinen M, Visakorpi T, Westermarck J. PLoS One. 2011 Mar 22;6(3):e17979. doi: 10.1371/journal.pone.0017979. 10.1371/journal.pone.0017979 PubMed 21445343
Related items: